GoodRx, 23andMe among health IT startups on CNBC's 'Disruptor 50' list

CNBC released the latest edition of its annual Disruptor 50 list on May 15, including several health and biotech startups among its ranking of private companies "whose innovations are changing the world."

The list was compiled by an advisory council of leaders in innovation and entrepreneurship who ranked the quantitative data of more than 1,200 nominated startups. Together, the 50 companies in the 2019 ranking have amassed more than $46 billion in venture capital, with a total market valuation of $266 billion.

Here are the nine health IT companies classified by CNBC as "disruptors" in their fields.

6. GoodRx (valuation: $2.8 billion): enables consumers to find and compare prescription prices at nearby pharmacies.

19. Ginkgo Bioworks (valuation: $1.4 billion): uses genetic engineering to design custom organisms for clients in pharmaceuticals and other fields.

20. YITU Technology (valuation: N/A): provides artificial intelligence solutions to industries including healthcare, where it has released AI-powered cancer-screening technology.

29. Virta Health (valuation: $320 million): offers medical supervision, personalized nutrition and health coaching, biomarker tracking and supplies in its efforts to reverse Type 2 diabetes.

30. Progyny (valuation: $123.1 million): helps large, self-insured companies offer fertility treatment coverage to employees.

34. Palantir (valuation: $20.5 billion): applies data analytics to streamlining processes for large organizations, including the National Institutes of Health, which recently awarded Palantir a $7 million contract to support its research initiatives.

39. Zipline International (valuation: N/A): delivers medicine, vaccines and blood supplies via drone in Rwanda and Ghana.

44. Veritas Genetics (valuation: N/A): screens 40,000 genes to provide consumers and their physicians with whole genome sequencing and interpretation of the results, outlining genetic predisposition to more than 1,200 conditions and potential drug reactions.

46. 23andMe (valuation: $2.5 billion): uses DNA testing to educate users about their ancestry and genetic health risks.

More articles about health IT:
HITAC passes info blocking recommendations for ONC proposed rule: 5 notes
Machine learning tool detects Alzheimer's in brain tissue
Elon Musk's neurotech startup falls short in funding round

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Top 40 Articles from the Past 6 Months